サバラ
Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.15 | $0 | -$33M |
| 2025 Q4 | -0.13 | $0 | -$25M |
| 2025 Q3 | -0.14 | $0 | -$23M |
| 2025 Q2 | -0.14 | $0 | -$26M |
| 2025 Q1 | -0.12 | $0 | -$27M |
| 2024 Q4 | -0.14 | $0 | -$23M |
| 2024 Q3 |
| -0.11 |
| $0 |
| -$23M |
| 2024 Q2 | -0.12 | $0 | -$23M |